CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2023-008155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Jiri Eitler und 18 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany t.tonn@blutspende.de j.e…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Breast Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Federal Ministry of Education and Research, German Red Cross Blood Donation Service internal grants, German Research Foundation.
Abstract (Originalsprache)
Background
The antitumor activity of natural killer (NK) cells can be enhanced by specific targeting with therapeutic antibodies that trigger antibody-dependent cell-mediated cytotoxicity (ADCC) or by genetic engineering to express chimeric antigen receptors (CARs). Despite antibody or CAR targeting, some tumors remain resistant towards NK cell attack. While the importance of ICAM-1/LFA-1 interaction for natural cytotoxicity of NK cells is known, its impact on ADCC induced by the ErbB2 (HER2)-specific antibody trastuzumab and ErbB2-CAR-mediated NK cell cytotoxicity against breast cancer cells has not been investigated.
Methods
Here we used NK-92 cells expressing high-affinity Fc receptor FcγRIIIa in combination with trastuzumab or ErbB2-CAR engineered NK-92 cells (NK-92/5.28.z) as well as primary human NK cells combined with trastuzumab or modified with the ErbB2-CAR and tested cytotoxicity against cancer cells varying in ICAM-1 expression or alternatively blocked LFA-1 on NK cells. Furthermore, we specifically stimulated Fc receptor, CAR and/or LFA-1 to study their crosstalk at the immunological synapse and their contribution to degranulation and intracellular signaling in antibody-targeted or CAR-targeted NK cells.
Results
Blockade of LFA-1 or absence of ICAM-1 significantly reduced cell killing and cytokine release during trastuzumab-mediated ADCC against ErbB2-positive breast cancer cells, but not so in CAR-targeted NK cells. Pretreatment with 5-aza-2'-deoxycytidine induced ICAM-1 upregulation and reversed NK cell resistance in ADCC. Trastuzumab alone did not sufficiently activate NK cells and required additional LFA-1 co-stimulation, while activation of the ErbB2-CAR in CAR-NK cells induced efficient degranulation independent of LFA-1. Total internal reflection fluorescence single molecule imaging revealed that CAR-NK cells formed an irregular immunological synapse with tumor cells that excluded ICAM-1, while trastuzumab formed typical peripheral supramolecular activation cluster (pSMAC) structures. Mechanistically, the absence of ICAM-1 did not affect cell–cell adhesion during ADCC, but rather resulted in decreased signaling via Pyk2 and ERK1/2, which was intrinsically provided by CAR-mediated targeting. Furthermore, while stimulation of the inhibitory NK cell checkpoint molecule NKG2A markedly reduced FcγRIIIa/LFA-1-mediated degranulation, retargeting by CAR was only marginally affected.
Conclusions
Downregulation of ICAM-1 on breast cancer cells is a critical escape mechanism from trastuzumab-triggered ADCC. In contrast, CAR-NK cells are able to overcome cancer cell resistance caused by ICAM-1 reduction, highlighting the potential of CAR-NK cells in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany t.tonn@blutspende.de j.eitler@blutspende.de.
- Institute for Transfusion Medicine Dresden, German Red Cross Blood Donation Service North-East, Dresden, Germany.
- German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany.
- Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
- Medical University of Vienna, Center for Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Vienna, Austria.
- TU Dresden, Medical Faculty and University Hospital Carl Gustav Carus, Department of Neurosurgery, Division of Experimental Neurosurgery and Tumor Immunology, Dresden, Germany.
ORCID-Profile: Jiri Eitler, Johannes B Huppa, Winfried S Wels, Torsten Tonn
Förderung
- Federal Ministry of Education and Research
- German Red Cross Blood Donation Service internal grants
- German Research Foundation
Zitieren
APA
Eitler, J., Rackwitz, W., Wotschel, N., Gudipati, V., Murali Shankar, N., Sidorenkova, A., Huppa, J. B., Ortiz-Montero, P., Opitz, C., Künzel, S. R., Michen, S., Temme, A., Loureiro, L. R., Feldmann, A., Bachmann, M., Boissel, L., Klingemann, H., Wels, W. S., & Tonn, T. (2024). CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-008155
Vancouver
Eitler J, Rackwitz W, Wotschel N, Gudipati V, Murali Shankar N, Sidorenkova A, et al. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-008155
BibTeX
@article{Eitler2024,
author = {Eitler, Jiri and Rackwitz, Wiebke and Wotschel, Natalie and Gudipati, Venugopal and Murali Shankar, Nivedha and Sidorenkova, Anastasia and Huppa, Johannes B and Ortiz-Montero, Paola and Opitz, Corinna and Künzel, Stephan R and Michen, Susanne and Temme, Achim and Loureiro, Liliana Rodrigues and Feldmann, Anja and Bachmann, Michael and Boissel, Laurent and Klingemann, Hans and Wels, Winfried S and Tonn, Torsten},
title = {CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2023-008155}
}
EUVIMED